Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?

Abhijeet Kumar, Srinath Sundararajan, Soham D Puvvada, Daniel O. Persky

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The seminal SWOG trial S8736 trial established the success of a short course of chemotherapy followed by involved field radiation in treating limited stage aggressive NHL lymphoma. Addition of rituximab offered a surprisingly modest improvement in this disease subset. Radioimmunotherapy could hold a slight advantage over rituximab, but that should be investigated in a randomized trial setting. The role of radiation therapy continues to be widely debated, with interpretation complicated by different trial populations, methods of assessing risk, as well as by differences in timing and dose of radiation. Prolonged course of chemotherapy followed by radiation is certainly not justified in all patients with limited stage disease. Three to four cycles of R-CHOP followed closely by IFRT/ISRT, or six cycles of R-CHOP chemoimmunotherapy (based on the MInT trial) are acceptable options. PET/CT scans may further limit radiation to minority of patients who have residual PET-positive masses. PET/CT-directed treatment strategy is being tested in a US intergroup trial. There is evidence that localized DLBCL has a different biology as compared to advanced stage disease. This relates to propensity of limited stage disease to be proportionately more germinal center B-cell like (GCB) and to have late relapses beyond 5 years. Both biology and imaging need to be integrated in the study of limited stage disease without presumption that it should be approached the same as advanced stage disease.

Original languageEnglish (US)
Article number45
JournalCurrent Treatment Options in Oncology
Volume17
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Non-Hodgkin's Lymphoma
Radiation
Therapeutics
Radioimmunotherapy
Drug Therapy
Germinal Center
Lymphoma
B-Lymphocytes
Radiotherapy
Recurrence
Population
Rituximab

Keywords

  • Diffuse large B-cell lymphoma
  • Limited stage
  • PET/CT scan
  • Radioimmunotherapy
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Limited Stage Aggressive Non-Hodgkin Lymphoma : What Is Optimal Therapy? / Kumar, Abhijeet; Sundararajan, Srinath; Puvvada, Soham D; Persky, Daniel O.

In: Current Treatment Options in Oncology, Vol. 17, No. 9, 45, 01.09.2016.

Research output: Contribution to journalReview article

Kumar, Abhijeet ; Sundararajan, Srinath ; Puvvada, Soham D ; Persky, Daniel O. / Limited Stage Aggressive Non-Hodgkin Lymphoma : What Is Optimal Therapy?. In: Current Treatment Options in Oncology. 2016 ; Vol. 17, No. 9.
@article{e724ff919b3c476db81c31e3e89c6246,
title = "Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?",
abstract = "The seminal SWOG trial S8736 trial established the success of a short course of chemotherapy followed by involved field radiation in treating limited stage aggressive NHL lymphoma. Addition of rituximab offered a surprisingly modest improvement in this disease subset. Radioimmunotherapy could hold a slight advantage over rituximab, but that should be investigated in a randomized trial setting. The role of radiation therapy continues to be widely debated, with interpretation complicated by different trial populations, methods of assessing risk, as well as by differences in timing and dose of radiation. Prolonged course of chemotherapy followed by radiation is certainly not justified in all patients with limited stage disease. Three to four cycles of R-CHOP followed closely by IFRT/ISRT, or six cycles of R-CHOP chemoimmunotherapy (based on the MInT trial) are acceptable options. PET/CT scans may further limit radiation to minority of patients who have residual PET-positive masses. PET/CT-directed treatment strategy is being tested in a US intergroup trial. There is evidence that localized DLBCL has a different biology as compared to advanced stage disease. This relates to propensity of limited stage disease to be proportionately more germinal center B-cell like (GCB) and to have late relapses beyond 5 years. Both biology and imaging need to be integrated in the study of limited stage disease without presumption that it should be approached the same as advanced stage disease.",
keywords = "Diffuse large B-cell lymphoma, Limited stage, PET/CT scan, Radioimmunotherapy, Rituximab",
author = "Abhijeet Kumar and Srinath Sundararajan and Puvvada, {Soham D} and Persky, {Daniel O.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s11864-016-0424-2",
language = "English (US)",
volume = "17",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "9",

}

TY - JOUR

T1 - Limited Stage Aggressive Non-Hodgkin Lymphoma

T2 - What Is Optimal Therapy?

AU - Kumar, Abhijeet

AU - Sundararajan, Srinath

AU - Puvvada, Soham D

AU - Persky, Daniel O.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The seminal SWOG trial S8736 trial established the success of a short course of chemotherapy followed by involved field radiation in treating limited stage aggressive NHL lymphoma. Addition of rituximab offered a surprisingly modest improvement in this disease subset. Radioimmunotherapy could hold a slight advantage over rituximab, but that should be investigated in a randomized trial setting. The role of radiation therapy continues to be widely debated, with interpretation complicated by different trial populations, methods of assessing risk, as well as by differences in timing and dose of radiation. Prolonged course of chemotherapy followed by radiation is certainly not justified in all patients with limited stage disease. Three to four cycles of R-CHOP followed closely by IFRT/ISRT, or six cycles of R-CHOP chemoimmunotherapy (based on the MInT trial) are acceptable options. PET/CT scans may further limit radiation to minority of patients who have residual PET-positive masses. PET/CT-directed treatment strategy is being tested in a US intergroup trial. There is evidence that localized DLBCL has a different biology as compared to advanced stage disease. This relates to propensity of limited stage disease to be proportionately more germinal center B-cell like (GCB) and to have late relapses beyond 5 years. Both biology and imaging need to be integrated in the study of limited stage disease without presumption that it should be approached the same as advanced stage disease.

AB - The seminal SWOG trial S8736 trial established the success of a short course of chemotherapy followed by involved field radiation in treating limited stage aggressive NHL lymphoma. Addition of rituximab offered a surprisingly modest improvement in this disease subset. Radioimmunotherapy could hold a slight advantage over rituximab, but that should be investigated in a randomized trial setting. The role of radiation therapy continues to be widely debated, with interpretation complicated by different trial populations, methods of assessing risk, as well as by differences in timing and dose of radiation. Prolonged course of chemotherapy followed by radiation is certainly not justified in all patients with limited stage disease. Three to four cycles of R-CHOP followed closely by IFRT/ISRT, or six cycles of R-CHOP chemoimmunotherapy (based on the MInT trial) are acceptable options. PET/CT scans may further limit radiation to minority of patients who have residual PET-positive masses. PET/CT-directed treatment strategy is being tested in a US intergroup trial. There is evidence that localized DLBCL has a different biology as compared to advanced stage disease. This relates to propensity of limited stage disease to be proportionately more germinal center B-cell like (GCB) and to have late relapses beyond 5 years. Both biology and imaging need to be integrated in the study of limited stage disease without presumption that it should be approached the same as advanced stage disease.

KW - Diffuse large B-cell lymphoma

KW - Limited stage

KW - PET/CT scan

KW - Radioimmunotherapy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84979619733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979619733&partnerID=8YFLogxK

U2 - 10.1007/s11864-016-0424-2

DO - 10.1007/s11864-016-0424-2

M3 - Review article

C2 - 27423794

AN - SCOPUS:84979619733

VL - 17

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 9

M1 - 45

ER -